KUMULUS-VAPE
28.5.2019 05:59:06 CEST | Business Wire | Press release
At 11.30 am this Tuesday, May 28 2019, shares in Kumulus Vape (ISIN: FR0013419876 - symbol: MLVAP) will be listed for the first time on the Euronext Access™ market in Paris (by technical admission). Kumulus Vape is an e-merchant specializing in the sale of electronic cigarettes and related 'vaping' products (equipment, e-liquids and accessories).
The listing on the Paris stock exchange is a first for European vape companies, marking a new milestone in the performance trajectory of the company from Lyon, a pioneer in its market in an active phase of development. The aim of this move is to enable Kumulus Vape to raise brand awareness and strengthen its presence on the domestic market.
55,000 shares will be offered for sale on the first day of market trading. This admission to the Euronext Access™ market constitutes a first step, prior to a possible transfer of Kumulus Vape shares to the Euronext Growth® market. The company seeks to introduce a dynamic of shares changing hands that could account for between 5 and 10% of the capital.
Established in 2012, Kumulus Vape is one of the main French online sites for the sale of vaping products (equipment, e-liquid, DIY1 ). With its broad range, comprising over 6,000 items, it offers products for both 'beginners' and vaping experts. As a committed player in combating tobacco and an advocate for the vaping sector, Kumulus Vape offers an unequalled choice of high-performing vaping products at low prices.
In 2018, Kumulus Vape's turnover was €6.5 million, up 116% on 2017. The EBITDA exceeded the €400,000 mark (+128% on 2017), with a net income of nearly €300,000 (+106%). In the first quarter of 2019, turnover rose by 96% to €2.3 million.
Kumulus Vape has a clear aim: to become one of the French leaders in 100% e-commerce vaping in the next three years.
Operating procedures
Listing market:
Euronext Access™
ISIN
:
FR0013419876
Symbol
: MLVAP
Registration procedure
:
technical admission
Number of shares in company capital
:
1,988,000
Number of shares sold on the day of listing
: 55,000
Sale
price per share
: €2.12
Valuation at time of listing
:
€4,214,560
Start of trading
: May 28, 2019
Eligible
for PEA (equity savings plan) and SME PEA
: yes
The operation does not require authorization from the French Financial Markets Authority (AMF). The information document has therefore not been approved by the AMF. The information document is available free of charge from the head office of Kumulus Vape. It may be downloaded from www.kumulusvape.fr/investisseurs . Please note that companies admitted to Euronext Access are not subject to the same rules as companies on the regulated market. Instead, they are subject to a smaller set of rules that is suitable for small businesses experiencing growth. The risk associated with an investment on Euronext Access may therefore be greater than investing in a company on the regulated market.
Partners in the operation
|
Atout Capital |
Consultant and listing sponsor |
|
|
Lamy Lexel |
Legal advice |
|
|
Mazars |
Auditors |
|
|
Actifin |
Financial communications |
|
About Kumulus Vape
Established in 2012, Kumulus Vape is one of the leading French distributors of e-cigarettes and e-liquids . With www.kumulusvape.fr , its website for individuals, and its wholesale business for specialist boutiques, the Company is positioned on both the B2C and B2B markets. Kumulus Vape's turnover rose to €6.5 million in 2018, representing a growth of 116% on 2017. Kumulus Vape is based in Corbas, just a few minutes from the south of Lyon, and currently has about 25 employees.
1 Do It Yourself: e-liquid base that people can use to create their own blends
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190527005309/en/
Contact:
KUMULUS VAPE Director of Communications Vincent Baudoin v.baudoin@kumulusvape.fr Tel.: 06 10 84 52 59
ACTIFIN Press relations Aminata Doucouré adoucoure@actifin.fr Tel.: 01 56 88 11 23
ACTIFIN Financial communications Julien Mouret jmouret@actifin.fr Tel.: 01 56 88 11 14
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance and Alibaba Announce Alibaba's Expanded Participation in the VDP Pool2.7.2026 02:00:00 CEST | Press release
Access Advance LLC and Alibaba Group today announced that Alibaba has joined the Access Advance Video Distribution Patent Pool (VDP Pool) as a Licensee, securing a license to the pool's comprehensive coverage of HEVC, VVC, VP9, and AV1 codec technologies. The announcement marks a milestone in a multi-year collaboration between the two companies that spans the VVC Advance Patent Pool, where Alibaba participates as both a Licensor and Licensee, and the VDP Pool, where Alibaba joined as a Licensor in 2025. Alibaba's subsidiary Youku, one of China's leading streaming platforms, also joined the VDP Pool as a Licensee in 2025. Alibaba operates one of the world's most diverse video ecosystems, spanning a wide range of video-based services across e-commerce, entertainment, and digital media. As video has become central to how consumers shop, communicate, and access entertainment, the breadth of Alibaba's video operations reflects the kind of business model complexity the VDP Pool was designed
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia2.7.2026 01:58:00 CEST | Press release
- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia -- Approximately 5,500 additional children in the U.S. are now eligible for this established one-time therapy, expanding upon the prior FDA approval in people 12 years and older -- Regulatory review for label expansion underway in the Kingdom of Saudi Arabia and United Kingdom - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY® (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT. “Just as we redefined what is possible in cystic fibrosis, our ambition is to transform
Andersen Global styrker sine kompetencer inden for skat og global mobilitet i Tyskland2.7.2026 00:13:00 CEST | Pressemeddelelse
Andersen Global styrker sin tilstedeværelse gennem en samarbejdsaftale med Lohr and Company (L+C), der er en erfaren skatterådgivningsvirksomhed, der leverer praktiske og fleksible løsninger inden for skattecompliance, internationale skatteforhold, global mobilitet og transfer pricing. L+C har hovedkontor i Tyskland og er også til stede i Østrig og rådgiver store multinationale selskaber, familieejede virksomheder, familievirksomheder, fonde og formuende privatpersoner. L+C blev grundlagt i 2001 og har specialiseret sig i global mobilitet, opkøb og fusioner, international skattelovgivning, rapportering mellem lande og transfer pricing, herunder rapportering i henhold til Pillar 2. Derudover bistår L+C sine kunder med trusts og fonde, skattecompliance, løn- og regnskabsadministration samt privatøkonomisk rådgivning. "Samarbejdet med Andersen Global er et vigtigt skridt i udvidelsen af vores internationale kompetencer og styrker den værdi, vi skaber for kunder, der navigerer i stadig mer
Robinhood Chooses Morpho to Power New Earn Product1.7.2026 21:15:00 CEST | Press release
Morpho now powers the infrastructure behind some of the most widely used retail financial platforms in the United States, bringing more options for onchain yield to millions of customers through the apps they already use. Morpho, the open blockchain-based credit network, today announced it will power Robinhood’s new Earn product, enabling Robinhood's millions of eligible users more options to earn yield onchain via a self-custody wallet, directly within the Robinhood app. The product will roll out progressively to Robinhood's US customer base over the coming weeks. The Robinhood Earn product aims to provide risk-adjusted yield on idle balances using USDG, a dollar-pegged stablecoin. Morpho serves as the underlying credit network, Steakhouse Financial curates the vault infrastructure supporting the product, and Robinhood Chain acts as the settlement layer. The product is delivered through a seamless experience in the Robinhood app. Morpho operates as an open network on the blockchain. L
Photonics Innovators Worldwide Invited to Compete for SPIE Prism Awards1.7.2026 20:33:00 CEST | Press release
19th annual award honors exceptional new products transforming light-based technologies SPIE, the international society of optics and photonics, invites the optics and photonics community to apply for this year’s SPIE Prism Awards, which recognize outstanding new products making waves on the market. Honorees will be announced at the highly-anticipated award ceremony on 3 February 2027 at SPIE Photonics West in San Francisco, California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701642411/en/ SPIE Prism Awards honor exceptional new products transforming optics and photonics technologies. These awards, dubbed the “Oscars of Photonics,” provide scientists and engineers in the optics and photonics industry the opportunity to showcase their contributions to the field. Finalists and winners receive extensive print, web, and onsite promotion at SPIE Photonics West, which draws more than 22,000 researchers and industry leade
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom